burosumab

Home
Ligands
burosumab

GtoPdb Ligand ID: 9292

Synonyms: burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023

burosumab is an approved drug (EMA & FDA (2018))

Comment: Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity [1,4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [11].

No information available.

No information available.

Summary of Clinical Use
Burosumab was approved by the EMA in March 2018, and this was quickly followed by FDA approval in April of the same year [6]. Burosumab is approved as a treatment for X-linked hypophosphatemia [3,8].

Summary of Clinical Use

Burosumab was approved by the EMA in March 2018, and this was quickly followed by FDA approval in April of the same year [6]. Burosumab is approved as a treatment for X-linked hypophosphatemia [3,8].

Mechanism Of Action and Pharmacodynamic Effects
X-linked hypophosphatemic (XLH) rickets is a rare disease that is caused by mutations in the PHEX gene (ORPHA:89936). Decreased expression of the PHEX-encoded endopeptidase leads to elevated serum FGF-23 (a phosphate-regulating hormone) levels and this reduces renal phosphate reabsorption [2,9-10]. The physiological outcome is hypophosphatemia which causes abnormal bone development and osteomalacia. Antibody-directed neutralisation of FGF-23 helps to restore phosphate levels in patients with XLH [5,7].

Mechanism Of Action and Pharmacodynamic Effects

X-linked hypophosphatemic (XLH) rickets is a rare disease that is caused by mutations in the PHEX gene (ORPHA:89936). Decreased expression of the PHEX-encoded endopeptidase leads to elevated serum FGF-23 (a phosphate-regulating hormone) levels and this reduces renal phosphate reabsorption [2,9-10]. The physiological outcome is hypophosphatemia which causes abnormal bone development and osteomalacia. Antibody-directed neutralisation of FGF-23 helps to restore phosphate levels in patients with XLH [5,7].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT02526160	Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)	Phase 3 Interventional	Ultragenyx Pharmaceutical Inc

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)